136 related articles for article (PubMed ID: 9006749)
21. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
[TBL] [Abstract][Full Text] [Related]
23. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
[TBL] [Abstract][Full Text] [Related]
24. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.
Solal-Celigny P; Lepage E; Brousse N; Reyes F; Haioun C; Leporrier M; Peuchmaur M; Bosly A; Parlier Y; Brice P
N Engl J Med; 1993 Nov; 329(22):1608-14. PubMed ID: 8232429
[TBL] [Abstract][Full Text] [Related]
25. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial.
Pettengell R; Gurney H; Radford JA; Deakin DP; James R; Wilkinson PM; Kane K; Bentley J; Crowther D
Blood; 1992 Sep; 80(6):1430-6. PubMed ID: 1381626
[TBL] [Abstract][Full Text] [Related]
26. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study.
Gregory SA; Case DC; Bosserman L; Litwak DL; Berry WR; Kalman LA; Belt RJ; Saven A
Clin Lymphoma; 2003 Sep; 4(2):93-8. PubMed ID: 14556680
[TBL] [Abstract][Full Text] [Related]
27. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study.
Niitsu N; Umeda M
Leukemia; 1997 Nov; 11(11):1817-20. PubMed ID: 9369412
[TBL] [Abstract][Full Text] [Related]
28. Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up.
Remick SC; Sedransk N; Haase RF; Blanchard CG; Ramnes CR; Nazeer T; Mastrianni DM; Dezube BJ
Am J Hematol; 2001 Mar; 66(3):178-88. PubMed ID: 11279624
[TBL] [Abstract][Full Text] [Related]
29. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
30. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
[TBL] [Abstract][Full Text] [Related]
31. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Zinzani PL; Pavone E; Storti S; Moretti L; Fattori PP; Guardigni L; Falini B; Gobbi M; Gentilini P; Lauta VM; Bendandi M; Gherlinzoni F; Magagnoli M; Venturi S; Aitini E; Tabanelli M; Leone G; Liso V; Tura S
Blood; 1997 Jun; 89(11):3974-9. PubMed ID: 9166835
[TBL] [Abstract][Full Text] [Related]
32. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
34. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis.
Morrison VA; Picozzi V; Scott S; Pohlman B; Dickman E; Lee M; Lawless G; Kerr R; Caggiano V; Delgado D; Fridman M; Ford J; Carter WB;
Clin Lymphoma; 2001 Jun; 2(1):47-56. PubMed ID: 11707870
[TBL] [Abstract][Full Text] [Related]
35. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
[TBL] [Abstract][Full Text] [Related]
36. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
37. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkins's lymphoma.
Niitsu N; Umeda M
Leukemia; 1998 Sep; 12(9):1457-60. PubMed ID: 9737696
[TBL] [Abstract][Full Text] [Related]
38. Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin: a randomized phase II study.
Tsurumi H; Yamada T; Sawada M; Kasahara S; Kanemura N; Kojima Y; Fukuno K; Hara T; Saio M; Takahashi T; Oyama M; Ozawa K; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2004 Feb; 130(2):107-13. PubMed ID: 14648210
[TBL] [Abstract][Full Text] [Related]
39. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
40. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.
Shipp MA; Neuberg D; Janicek M; Canellos GP; Shulman LN
J Clin Oncol; 1995 Dec; 13(12):2916-23. PubMed ID: 8523055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
